| Drug Name |
Maprotiline hydrochloride |
| Drug ID |
BADD_D01351 |
| Description |
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. |
| Indications and Usage |
For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis. |
| Marketing Status |
approved; investigational |
| ATC Code |
N06AA21 |
| DrugBank ID |
DB00934
|
| KEGG ID |
D00818
|
| MeSH ID |
D008376
|
| PubChem ID |
71478
|
| TTD Drug ID |
D03KQF
|
| NDC Product Code |
17337-0527 |
| UNII |
7C8J54PVFI
|
| Synonyms |
Maprotiline | Maprotilin | N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine | Dibencycladine | Psymion | Ludiomil | Maprolu | Maprotilin Holsten | maprotilin von ct | Maprotilin-neuraxpharm | Maprotilin neuraxpharm | Maprotilin-ratiopharm | Maprotilin ratiopharm | Maprotilin-TEVA | Maprotilin TEVA | Maprotiline Hydrochloride | Hydrochloride, Maprotiline | Maprotiline Mesylate | Mesylate, Maprotiline | Mirpan | Novo-Maprotiline | Novo Maprotiline | Ba-34,276 | Ba34,276 | Deprilept |
